Docsity
Docsity

Prepare for your exams
Prepare for your exams

Study with the several resources on Docsity


Earn points to download
Earn points to download

Earn points by helping other students or get them with a premium plan


Guidelines and tips
Guidelines and tips

Clinical Pharmacy Practice Model Description of Model Key ..., Study notes of Pharmacy

The pharmaceutical care model is now defined as a patient-centered way to deliver medication manage- ment services. The model stresses.

Typology: Study notes

2021/2022

Uploaded on 09/27/2022

scrooge
scrooge 🇬🇧

4.5

(11)

247 documents

1 / 5

Toggle sidebar

This page cannot be seen from the preview

Don't miss anything!

bg1
Clinical Pharmacy
Practice Model Description of Model Key Elements Steps
Pharmaceutical
care1
The pharmaceutical care model is
now defined as a patient-centered
way to deliver medication manage-
ment services. The model stresses
a pharmacist’s responsibility for a
patient’s drug-related needs and
being held accountable for the com-
mitment. The purpose is to achieve
positive patient outcomes. The phar-
macist ensures that all of a patient’s
drug therapy is indicated, effective,
and safe and that the patient is able
and willing to adhere to instructions.
It is a generalist practice, consistent
with the concepts of primary care
and the medical home.
The pharmaceutical care model has three key com-
ponents:
1) Identify a patient’s actual and potential drug
therapy problems (DTPs).
2) Resolve actual DTPs.
3) Prevent potential DTPs from becoming actual
DTPs.
The pharmaceutical care process has three key
steps:
1) ASSESS
2) CARE PLAN
3) EVALUATION
In the standards of care for pharmaceutical care,
the practitioner:
1) Collects patient-specific information to use in
decision-making regarding all drug therapies
2) Analyzes assessment data to determine that
drug-related needs are being met; that all medica-
tions are indicated, effective, and safe; and that
the patient is able and willing to take the medica-
tion as intended.
3) Analyzes assessment data to determine whether
any DTPs are present
4) Identifies goals of therapy that are patient-cen-
tered
5) Develops a care plan including interventions
to resolve DTPs, achieve goals of therapy, and
prevent DTPs
6) Develops a schedule to follow up and evalu-
ate the effectiveness of drug therapies and any
adverse events experienced by the patient
7) Evaluates the patient’s outcomes and determines
progress toward achieving goals of therapy, iden-
tifies safety and adherence issues, and assesses
whether new DTPs have developed
1) ASSESSMENT of patient’s drug-related needs
Includes a pharmacotherapy workup and a full review of systems to identify DTPs.
All DTPs are categorized and must fall under one of four categories, composed of
seven types of DTPs:
a. Indication
i. Unnecessary drug therapy
ii. Needs additional drug therapy
b. Effectiveness
i. Ineffective drug
ii. Dosage too low
c. Safety
i. Adverse drug reaction
ii. Dosage too high
d. Adherence
i. Patient not able or willing to take medication
2) CARE PLAN development to meet patient’s needs
Four categories of interventions are selected to establish goals of therapy:
a. Resolve DTPs.
b. Achieve goals of therapy.
c. Prevent future DTPs.
d. Schedule follow-up.
Types of interventions that can occur:
a. Initiate new drug therapy.
b. Change dosage regimen.
c. Change the drug product.
d. Discontinue drug therapy.
e. Institute a monitoring plan.
f. Patient-specific instructions
g. Removal of barriers to obtain medication
h. Drug administration device provided
i. Refer patient.
3) Follow-up EVALUATION
Each condition is categorized into eight predetermined outcomes:
a. Resolved
b. Stable
c. Improved
d. Partly improved
e. Unimproved
f. Worsened
g. Failure
h. Expired (patient died)
pf3
pf4
pf5

Partial preview of the text

Download Clinical Pharmacy Practice Model Description of Model Key ... and more Study notes Pharmacy in PDF only on Docsity!

Practice Model Description of Model Key Elements Steps

Pharmaceutical care 1

The pharmaceutical care model is now defined as a patient-centered way to deliver medication manage- ment services. The model stresses a pharmacist’s responsibility for a patient’s drug-related needs and being held accountable for the com- mitment. The purpose is to achieve positive patient outcomes. The phar- macist ensures that all of a patient’s drug therapy is indicated, effective, and safe and that the patient is able and willing to adhere to instructions. It is a generalist practice, consistent with the concepts of primary care and the medical home.

The pharmaceutical care model has three key com- ponents:

  1. Identify a patient’s actual and potential drug therapy problems (DTPs).
  2. Resolve actual DTPs.
  3. Prevent potential DTPs from becoming actual DTPs.

The pharmaceutical care process has three key steps:

  1. ASSESS
  2. CARE PLAN
  3. EVALUATION

In the standards of care for pharmaceutical care, the practitioner:

  1. Collects patient-specific information to use in decision-making regarding all drug therapies
  2. Analyzes assessment data to determine that drug-related needs are being met; that all medica- tions are indicated, effective, and safe; and that the patient is able and willing to take the medica- tion as intended.
  3. Analyzes assessment data to determine whether any DTPs are present
  4. Identifies goals of therapy that are patient-cen- tered
  5. Develops a care plan including interventions to resolve DTPs, achieve goals of therapy, and prevent DTPs
  6. Develops a schedule to follow up and evalu- ate the effectiveness of drug therapies and any adverse events experienced by the patient
  7. Evaluates the patient’s outcomes and determines progress toward achieving goals of therapy, iden- tifies safety and adherence issues, and assesses whether new DTPs have developed

1) ASSESSMENT of patient’s drug-related needs Includes a pharmacotherapy workup and a full review of systems to identify DTPs. All DTPs are categorized and must fall under one of four categories, composed of seven types of DTPs: a. Indication i. Unnecessary drug therapy ii. Needs additional drug therapy b. Effectiveness i. Ineffective drug ii. Dosage too low c. Safety i. Adverse drug reaction ii. Dosage too high d. Adherence i. Patient not able or willing to take medication 2) CARE PLAN development to meet patient’s needs Four categories of interventions are selected to establish goals of therapy: a. Resolve DTPs. b. Achieve goals of therapy. c. Prevent future DTPs. d. Schedule follow-up. Types of interventions that can occur: a. Initiate new drug therapy. b. Change dosage regimen. c. Change the drug product. d. Discontinue drug therapy. e. Institute a monitoring plan. f. Patient-specific instructions g. Removal of barriers to obtain medication h. Drug administration device provided i. Refer patient. 3) Follow-up EVALUATION Each condition is categorized into eight predetermined outcomes: a. Resolved b. Stable c. Improved d. Partly improved e. Unimproved f. Worsened g. Failure h. Expired (patient died)

Practice Model Description of Model Key Elements Steps

Medication therapy management

(MTM) 2

MTM is defined as a distinct service or group of services that optimize therapeutic outcomes for individual patients. In this model, the patient is empowered to take an ac- tive role in managing his or her medications.

All MTM services should include: (1) Establishing a pharmacist-patient relationship in which the pharmacist provides individualized services specific to the patient (or caregiver) to whom services are provided (2) The interaction between the patient (or caregiver) and pharmacist preferably occurs through face-to- face communication. (3) Opportunities for pharmacists and other quali- fied health care providers to identify patients who should receive MTM services (4) Payment for MTM services consistent with con- temporary provider payment rates (5) Processes to improve continuity of care, out- comes, and outcome measures

The MTM service model has five core elements: 1) Medication therapy review (MTR) A systematic process of collecting patient-specific information a. Assessing medications to identify medication-related problems (MRPs) by reviewing indication, effectiveness, safety, and adherence b. Developing a prioritized list of MRPs c. Creating a plan to resolve MRPs Two main types of MTR: a. Comprehensive: annual and after transitions of care b. Targeted: addresses specific MRP 2) Personal medication record (PMR) a. A comprehensive record of all medications (prescription, over-the-counter, herbal, and other dietary supplements), which is intended for patients to use in medication self-management b. Can be created as part of discharge process in the institutional setting or as part of patient care in the ambulatory care setting c. Patients are responsible for documenting any changes to their therapeutic regimens to ensure a current and accurate record. 3) Medication-related action plan (MAP) a. Intended for patient use; contains a list of actions for self-management The pharmacist-created MAP includes items the patient can act on that are within the pharmacist’s scope of practice or agreed on by other mem- bers of the health care team. 4) Intervention and/or referral Recommendations on selection of medications; options to address MRPs, recom- mended monitoring parameters, and follow-up care 5) Documentation and follow-up a. MTM services should be documented in a consistent manner, and follow-up MTM visits are scheduled on the basis of the individual patient’s medication-related needs. b. Documentation for patients may include the PMR, MAP, and educational materials. c. Documentation to physicians may include a cover letter, the patient’s PMR, the SOAP note, and the care plan.

Practice Model Description of Model Key Elements Steps

SHPA

(Society of Hospital Pharmacists of Australia) 4

The SHPA developed Standards of Practice for clinical pharmacy with the objective to “optimize patient outcomes by work- ing to achieve the quality use of medicines (QUM).” Clinical pharmacy practice is defined as “the practice of pharmacy as part of a multidisciplinary health care team directed at achieving QUM.”

The document includes not only a model of practice, but also the other types of activities clinical pharmacists may be engaged in, including rounding, providing drug information to health pro- fessionals and patients, reporting and managing adverse drug reactions, and participating in research.

The standards define the procedures for clinical phar- macy services for individual patients in great detail. In these standards, the two overlapping components are (1) a MAP and (2) the discrete clinical activities that contribute to the plan.

The MAP focuses on overall patient outcomes, and it states that to carry out the plan, a pharmacist will perform several specific clinical activities. The MAP contains six fundamental components:

a. Interpretation of patient-specific data b. Identification of clinical problems (focus on prob- lems that require their expertise) c. Establishment of therapeutic goals d. Evaluation of therapeutic options e. Individualization of therapy f. Monitoring of patient outcomes

10 specific clinical activities that contribute to the components of a MAP:

  1. Accurate medication history
  2. Assessment of current medication management
  3. Clinical review
  4. Decision to prescribe a medicine
  5. Therapeutic drug monitoring
  6. Participation in multidisciplinary ward rounds and meetings
  7. Provision of medicine information to health professionals
  8. Provision of medicine information to patients
  9. Information for ongoing care
  10. Adverse drug reaction management

For each of the above clinical activities, an appendix is provided. Each activity description then has an introduction section, goals for the activity, procedures for the activity (extensive), and a role for a pharmacy technician with the activity (if applicable).

The standards also provide guidance on documenting clinical activities and the MAP.

Practice Model Description of Model Key Elements Steps

iMAP program

(individualized medication assess- ment and planning) (Mary Roth, per- sonal communica- tion, May 2012)

The iMAP program is a patient- centered, comprehensive MTM program. The program consists of 10 essential steps in the provision of patient care. Although it is being studied in those 65 years and older, it is applicable to other age groups, especially patients with multiple comorbidities and using multiple medications.

A full description of this model is not available at this time.

The iMAP program is outlined in 10 essential steps. Care along each step is individualized to meet the needs of the patient. Several steps of the process are further described, including conducting a compre- hensive medication review, identifying MRPs, and documenting encounters.

For example, when assessing and documenting MRPs, the clinical pharmacist is guided by the iMAP tool (REF #5). This tool categorizes MRPs into seven general categories. Several subcategories under each large category are provided to further classify the MRP. The general categories are:

  1. Drug therapy needed
  2. Suboptimal dosing
  3. Medication monitoring needed
  4. Suboptimal drug
  5. Adverse drug event present
  6. Suboptimal duration, administration, or frequency
  7. Nonadherence

Once an MRP is identified and documented, a recom- mendation or intervention is proposed to the primary care provider, consensus is reached, and the plan is implemented to optimize medication use. To track interventions made by the clinical pharmacist, a list of 20 possible recommendations is included as part of the iMAP tool to document the intervention used to resolve the MRP (e.g., add a drug, discontinue a drug, decrease a dose, increase a dose, switch to a more effective agent).

The 10 steps in this MTM model:

  1. Review and synthesize information from medical record.
  2. Conduct comprehensive medication review with patient.
  3. Identify MRPs.
  4. Formulate assessment/propose plan to optimize medication use.
  5. Communicate proposed plan to primary care provider.
  6. Implement plan once consensus is reached.
  7. Educate patient.
  8. Document plan in medical record and provide written summary to patient.
  9. Reconcile medications at all encounters, when possible, including transitions of care.
  10. Provide ongoing face-to-face and telephone follow-up.